



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 70999

Title: Immunotherapy in triple-negative breast cancer (TNBC): A literature review and new advances

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05232251

Position: Peer Reviewer

Academic degree: MBBS, MD

Professional title: Senior Consultant, Chief Doctor

Reviewer's Country/Territory: India

Author's Country/Territory: Peru

Manuscript submission date: 2021-08-22

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-09-22 03:54

Reviewer performed review: 2021-09-22 05:05

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

The topic appears interesting. However, the entire manuscript is written in a haphazard manner. The drug trials are mixed with biomarkers. More clarity is required.



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 70999

Title: Immunotherapy in triple-negative breast cancer (TNBC): A literature review and new advances

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05387238

Position: Editorial Board

Academic degree: PhD

Professional title: Associate Research Scientist

Reviewer's Country/Territory: Israel

Author's Country/Territory: Peru

Manuscript submission date: 2021-08-22

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-10-04 11:48

Reviewer performed review: 2021-10-04 12:47

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

This interesting review includes an update of the advances in immunotherapy for TNBC. The review is summarizing distinct ongoing clinical trials using anti PD-L1 antibodies in metastatic and early -neoadjuvant, adjuvant TNBC treatment. The review is written in a very comprehensive and clear way, granting the information about the last advances in immunotherapy for the already unmet clinical need TNBC. Comments: Please update about atezolizumab therapy concerns and the new data presented by Roche. Update the last FDA approval (July 2021) of Pembrolizumab + chemotherapy in the neoadjuvant regimen for TNBC. Minor comment: Page 12, line 11: Replace Another with Other